For the roughly 200 million people worldwide who take a statin every day, the routine is deceptively simple: swallow a pill, ...

Twice a year, a nurse slides a small needle under the skin of your upper arm. Thirty seconds later, you are done. No daily ...

GIP infusion as add-on to placebo or semaglutide did not improve glycaemic control in individuals with type 2 diabetes at the prespecified target of 1·50 mmol/L. Due to dropouts, we cannot draw firm ...

A new treatment option, SubQ, is helping some lung cancer patients spend less time in the clinic and more time living their lives.Shelby spoke with lung cancer patient Stephanie Williams and Dr. Coral ...

FDA’s three-month extension was triggered by a major amendment after the agency requested additional information during priority review, necessitating more time to evaluate newly submitted materials.

AI development company Subquadratic has announced its AI model, ' SubQ.' SubQ is a model developed with an architecture different from mainstream Transformer-based AI models and boasts a massive ...

A little-known Miami-based startup called Subquadratic emerged from stealth on Tuesday with a sweeping claim: that it has built the first large language model to fully escape the mathematical ...

AI thrives on data but feeding it the right data is harder than it seems. As enterprises scale their AI initiatives, they face the challenge of managing diverse data pipelines, ensuring proximity to ...

Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...

Knee osteoarthritis is a complex disease that affects the whole joint, including bone, cartilage, ligaments and muscles. Osteoarthritis is a common cause of pain and movement difficulty, affecting 8.3 ...

Y our oncologist may prescribe immunotherapy at various points in the cancer treatment journey. Immunotherapy is known to be especially effective in treating late-stage cancer that hasn’t responded to ...

After attracting GSK with its subcutaneous delivery tech at the top of the year, South Korea’s Alteogen has snared another Big Pharma partner in Biogen. Biogen will hand Alteogen $20 million upfront ...